Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda.
Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda.
复制标题
DOI：
10.1038/s41564-021-00933-9
复制
发表时间：
2021-08
影响因子：
28.3
通讯作者：
Cotten M
中科院分区：
文献类型：
--
作者：
Bugembe DL;Phan MVT;Ssewanyana I;Semanda P;Nansumba H;Dhaala B;Nabadda S;O'Toole ÁN;Rambaut A;Kaleebu P;Cotten M
在这里，我们报告了2020年3月至2021年1月在乌干达进行的SARS-CoV-2基因组监测，乌干达是一个内陆东非国家，人口约为4000万。我们从39，424例报告的SARS-CoV-2感染中报告了322例完整的SARS-CoV-2基因组，占报告病例的0.8%。这些序列的系统发育分析揭示了谱系A.23.1从谱系A.23的出现。谱系A.23.1占2020年12月观察到的基因组的88%，然后占2021年1月观察到的基因组的100%。在其他26个国家也报告了A.23.1谱系。尽管A.23.1中的精确变化与前三种SARS-CoV-2变异体（VOC）中报告的变化不同，但A.23.1刺突蛋白编码区具有与VOC相似的变化，包括位置613处的变化、延伸碱性氨基酸基序的弗林蛋白酶切割位点的变化和免疫原性N末端结构域的多个变化。此外，A.23.1谱系的非刺突蛋白（包括nsp 6、ORF 8和ORF 9）也发生了变化，这些变化在其他VOC中也发生了变化。A.23.1变体的临床影响尚不清楚，也未被指定为VOC。然而，我们对这种变体的出现和传播的发现表明，谨慎监测这种变体，并评估刺突蛋白变化对COVID-19疫苗性能的影响是可取的。SARS-CoV-2变异体A.23.1在乌干达占主导地位，其S蛋白和非刺突蛋白中的氨基酸变化与已知的相关变异体相似。
Here, we report SARS-CoV-2 genomic surveillance from March 2020 until January 2021 in Uganda, a landlocked East African country with a population of approximately 40 million people. We report 322 full SARS-CoV-2 genomes from 39,424 reported SARS-CoV-2 infections, thus representing 0.8% of the reported cases. Phylogenetic analyses of these sequences revealed the emergence of lineage A.23.1 from lineage A.23. Lineage A.23.1 represented 88% of the genomes observed in December 2020, then 100% of the genomes observed in January 2021. The A.23.1 lineage was also reported in 26 other countries. Although the precise changes in A.23.1 differ from those reported in the first three SARS-CoV-2 variants of concern (VOCs), the A.23.1 spike-protein-coding region has changes similar to VOCs including a change at position 613, a change in the furin cleavage site that extends the basic amino acid motif and multiple changes in the immunogenic N-terminal domain. In addition, the A.23.1 lineage has changes in non-spike proteins including nsp6, ORF8 and ORF9 that are also altered in other VOCs. The clinical impact of the A.23.1 variant is not yet clear and it has not been designated as a VOC. However, our findings of emergence and spread of this variant indicate that careful monitoring of this variant, together with assessment of the consequences of the spike protein changes for COVID-19 vaccine performance, are advisable. The SARS-CoV-2 variant A.23.1 became predominant in Uganda and shows amino acid changes within the S protein and non-spike proteins similar to known variants of concern.
登录
查看更多内容
乌干达 SARS-CoV-2 的主要进入途径和基因组多样性。
影响因子：
11.8
作者：
Bugembe DL;Kayiwa J;Phan MVT;Tushabe P;Balinandi S;Dhaala B;Lexow J;Mwebesa H;Aceng J;Kyobe H;Ssemwanga D;Lutwama J;Kaleebu P;Cotten M
通讯作者：
Cotten M
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
影响因子：
5.3
作者：
Cotten M;Lule Bugembe D;Kaleebu P;V T Phan M
通讯作者：
V T Phan M
影响因子：
10.7
作者：
Darriba, Diego;Posada, David;Flouri, Tomas
通讯作者：
Flouri, Tomas
影响因子：
7.6
作者：
Chang CK;Hou MH;Chang CF;Hsiao CD;Huang TH
通讯作者：
Huang TH